Answers are grounded in this paper and cite their sources.
Retrospective analysis shows tumor stage and mitotic index influence prognosis in ovarian tumors, highlighting the need for early diagnosis and optimal therapy.
Aims: Sex cord stromal tumors (SCSTs) constitute a rare subgroup of ovarian tumors, exhibiting heterogeneous clinical course and prognosis. The aim of this study is to evaluate clinicopathological factors affecting prognosis in patients with SCSTs based on single-center experience. Methods: This retrospective study included patients diagnosed with SCSTs at Selçuk University between 2010-2025. Demographic characteristics, tumor type, tumor stage, tumor size, mitotic index, surgical approach, adjuvant therapy status, and follow-up duration were recorded. Factors affecting prognosis were analyzed in terms of overall survival and disease-free survival. Results: A total of 94 patients with ovarian SCSTs were included in the study. Granulosa cell tumors constituted the most common histopathological subtype (n=41, 43.6%), followed by fibroma/thecoma (n=25, 26.6%) and other SCSTs (n=28, 29.8%). The mean age at diagnosis was 58.0±14.6 years. Tumor recurrence was observed in 5 patients (5.3%). At the last follow-up, 79 patients (84.0%) were alive and 15 patients (16.0%) had died. Adjuvant therapy was administered to 6 patients (6.4%), all of whom belonged to the other SCST group. Recurrence and mortality were more frequently observed in granulosa cell tumor and other SCST subgroups. Conclusion: In SCSTs, stage, mitotic activity, and residual disease after surgery are important factors in determining prognosis. Early diagnosis and optimal cytoreduction positively influence disease-free and overall survival. Larger patient series and multicenter studies with long-term follow-up are needed.
No takes yet. Share an insight, caveat, or question.
Özdemir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: